🇺🇸 FDA
Patent

US 11365250

Compositions and methods for cancer therapy

granted A61KA61K2039/505A61K38/177

Quick answer

US patent 11365250 (Compositions and methods for cancer therapy) held by The Board of Regents of the University of Texas System expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/505, A61K38/177, A61P, A61P25/00